Fragile X Syndrome Market Size, Share & Trends Analysis Report By Treatment (Ssris, Psychostimulants, Atypical Antipsychotics, Anticonvulsants, Antihypertensive Anxiolytics, Benzodiazepines, Lithium, Other Antidepressants), Region And Segment Forecasts, 2023-2031.

The Fragile X Syndrome Market Size is valued at 20.80 Million in 2022 and is predicted to reach 37.71 Million by the year 2031 at a 7.0 % CAGR during the forecast period for 2023-2031. 

Fragile X syndrome is a hereditary condition that causes a range of neurological problems, including cognitive impairment and learning disabilities. Males are more affected compare to females by this disorder. It causes delayed development of speech and language by age 2. Affected children may develop attention deficit disorder; about one-third of individuals may develop autism, and in about 15% of male and 5% of female seizure occurs. Most males and about half of females with fragile X syndrome have characteristic physical features that become more prominent with age. These features include large ears, a long and narrow face, unusually flexible fingers, flat feet, a prominent jaw and forehead, and in males, enlarged testicles after puberty. It is estimated that approximately 1 in 2500-4000 males and 1 in 7000-8000 females.

Market Segmentation

The global Fragile X syndrome market is segmented on the basis of treatment and geography. On the basis of treatment, the global Fragile X syndrome is further segmented into Ssris, Psychostimulants, Atypical Antipsychotics, Anticonvulsants, Antihypertensive Anxiolytics, Benzodiazepines, Lithium, Other Antidepressants. However, treatment and intervention are focused to improve the lives of affected individuals. The majority of pipeline molecules (gaboxadol, etc.) for the treatment of Fragile X Syndrome are currently in phase 2 of development are expected to come into the market in the forecast period. An increase in incidence and prevalence of Fragile X Syndrome expected to boost the growth of the market in forecast period. In addition to it, ongoing clinical trials and growing licensing and acquisition deals will further drives the growth of the market. However, stringent government regulation, complex disease mechanism, and disappointing results of promising pipeline molecules hampers the development of the Fragile X syndrome market during the forecast period. Furthermore, a lack of awareness among people regarding genetic disorders restrains the growth of the market.

At regional level, the global Fragile X syndrome market has been segmented into North America, Europe, Asia Pacific, Latin America and Middle East & Africa. In terms of revenue, North America followed by Europe is major contributor for the global Fragile X syndrome market. This is because strong clinical pipeline, increasing research and drug development activities, presence of major players, and presence of developed healthcare infrastructure propels the growth of the market in the region. Asia Pacific is third promising revenue contributor which is expected to grow at rapid pace in upcoming year. Countries such as Japan, India and China are major contributors for this market. Emerging and huge population base countries such as China and India offers tremendous market opportunities for the Fragile X syndrome market.

Competitive Landscape

Some of The Key Players in The Fragile X Syndrome Market:

• Acadia Pharmaceuticals
• Advanz Pharma Corp
• Boehringer Ingelheim
• Confluence Pharmaceuticals
• Eli Lilly
• GlaxoSmithKline
• Lundbeck
• Janssen
• Neuren Pharmaceuticals
• Novartis
• Otsuka Pharmaceuticals
• Sanofi
• Takeda
• Viatris
• Tetra Therapeutics
• Hoffmann-La Roche Ltd
• Shionogi & Co Ltd
• Ovid Therapeutics Inc
• Anavex Life Sciences Corp
• Arcturus Therapeutics Holdings Inc
• Autifony Therapeutics Ltd
• Zynerba Pharmaceuticals

The Fragile X Syndrome Market Report Scope